Dr. Martens (LON:DOCS) Stock Price Down 13.7% – Time to Sell?

Dr. Martens plc (LON:DOCS) fell 13.7% during trading on Tuesday . The company traded as low as GBX 65 and last traded at GBX 65.29. 3,337,086 shares traded hands during trading, an increase of 93% from the average session volume of 1,727,242 shares. The stock had previously closed at GBX 75.65.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DOCS shares. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Performance

The stock’s 50 day simple moving average is GBX 76.53 and its two-hundred day simple moving average is GBX 83.47. The company has a market cap of £634.55 million, a PE ratio of 38.62, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, research analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insider Activity

In other news, insider Robert Hanson bought 96,000 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was acquired at an average price of GBX 79 per share, for a total transaction of £75,840. In the last three months, insiders bought 97,130 shares of company stock worth $7,673,816. 2.79% of the stock is currently owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.